During their June 25th presentation at the JMP Securities Healthcare Conference (audio file), Dr. Lewis and Dr. Lebel spent a good chunk of their time discussing "the power of the platform" and Ziopharm's (NASDAQ:ZIOP) budding interest in chimeric antigen receptor CAR T cells. It wasn't clear at the time how the company would carry out their CAR ambitions, but many investors expected a partnership deal. More recently, Ziopharm put out a press release announcing their CAR program would move forward as a collaboration with Intrexon (NYSE:XON). Intrexon is already the source of Ziopharm's entire pipeline and owns 50% of any future revenue Ziopharm may earn. While Intrexon has spent a large percentage of their...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|